- ►diabetesjournals.org MH Noyan-Ashraf, MA Momen, K Ban, AM Sadi … - Diabetes, 2009 - Am Diabetes Assoc OBJECTIVE Glucagon-like peptide-1 receptor (GLP-1R) agonists are used to treat
type 2 diabetes, and transient GLP-1 administration improved cardiac function in
humans after acute myocardial infarction (MI) and percutaneous ... Cited by 5 - Related articles - All 3 versions
L Timmers, JPS Henriques, DPV de Kleijn, JH … - Journal of the American College of Cardiology, 2009 - Am Coll Cardio Found Still not a subscriber to JACC Imaging or JACC Interventions? ... Manuscript
received June 23, 2008; revised manuscript received October 20, 2008, accepted
October 20, 2008. ... Objectives: This study sought to examine whether ... Cited by 10 - Related articles - All 19 versions
JP Courreges, T Vilsbøll, M Zdravkovic, T Le- … - Diabetic Medicine, 2008 - pubmedcentral.nih.gov We present here the effect of liraglutide on biomarkers for cardiovascular risk
in patients with Type 2 diabetes, as an exploratory endpoint from a broader
clinical study. The design and non-cardiovascular biomarker results of this ... Cited by 10 - Related articles - All 5 versions
DJ Grieve, RS Cassidy, BD Green - British Journal of Pharmacology, 2009 - interscience.wiley.com Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted by the small
intestine in response to nutrient ingestion. It has wide-ranging effects on
glucose metabolism, including stimulation of insulin release, inhibition of ... Cited by 1 - Related articles - All 3 versions
UM Mortensen, BL Norgaard, JE Nielsen- … - Basic research in cardiology, 2006 - Springer Abstract ATP-sensitive potassium channels are opened during the course of
ischemic preconditioning (IP). As experimental data suggest that opening of
sarcolemmal ATP-sensitive potassium channels underlie ST elevation dur- ing ... Cited by 1 - Related articles - BL Direct - All 4 versions
F Lin, R Wang - Journal of Molecular Modeling, 2009 - Springer Abstract Glucagon-like peptide-1 receptor (GLP-1R) is a promising molecular
target for developing drugs treating type 2 diabetes. We have predicted the
complete three- dimensional structure of GLP-1R and the binding modes of ... Cited by 1 - Related articles - All 3 versions
J Kristensen - Danish Medical Bulletin, 2006 - danmedbul.dk The project was performed at Department of Nuclear Medicine, Cardiology and
Clinical Institute, Skejby Hospital, and consists of four experimental
substudies. The main issues were the use of sestamibi-SPECT as outcome ... Cited by 1 - Related articles - Cached - BL Direct - All 4 versions
